...
首页> 外文期刊>Journal of Medical Microbiology: An Official Journal of the Pathological Society of Great Britain and Ireland >Improving turnaround time for identifying extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: experience with the BD Phoenix automated system
【24h】

Improving turnaround time for identifying extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: experience with the BD Phoenix automated system

机译:缩短确定生产广谱β-内酰胺酶的大肠杆菌和肺炎克雷伯菌的周转时间:BD Phoenix自动化系统的经验

获取原文
           

摘要

Infections by resistant organisms such asextended-spectrum b -lactamase (ESBL)-producing bacteria represent an increasedrisk of therapeutic failure and areassociated with longer duration of hospitalstay and higher hospital charges. Over thelast decade, Escherichia coli and Klebsiellapneumoniae have been associated withepidemic clones harbouring virulencefactors and multiresistance (Rodr? ′guez-Ban ?o & Pascual, 2008). Thus, it isnecessary to rapidly identify ESBL-producing bacteria to control theirdissemination and to select appropriateantimicrobial therapy (Pitout & Laupland,2008), which is usually non- b -lactams suchas imipenem, fluoroquinolones orcotrimoxazole.
机译:产生耐药谱的细菌,例如产生超广谱β-内酰胺酶(ESBL)的细菌的感染代表了治疗失败的风险增加,并且该地区的住院时间更长,住院费用更高。在过去的十年中,大肠杆菌和肺炎克雷伯氏菌与携带病毒因子和多重耐药性的流行性克隆相关(Rodr?'guez-Ban?o&Pascual,2008)。因此,有必要迅速鉴定出产生ESBL的细菌以控制其传播并选择适当的抗菌疗法(Pitout&Laupland,2008),该疗法通常是非β-内酰胺类,如亚胺培南,氟喹诺酮或cotrimoxoxazole。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号